ONCS BRAS |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.83 BRL | -2.15% |
|
-6.69% | -47.46% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 670.77Cr 130.27Cr 11TCr | Sales 2025 * | 765.53Cr 148.68Cr 12TCr | Capitalization | 354.78Cr 69Cr 5.75TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 38Cr 7.34Cr 612.7Cr | Net income 2025 * | 52Cr 10Cr 834.76Cr | EV / Sales 2024 * | 1.16 x |
| Net Debt 2024 * | 426.21Cr 83Cr 6.91TCr | Net Debt 2025 * | 384.58Cr 75Cr 6.23TCr | EV / Sales 2025 * | 0.97 x |
| P/E ratio 2024 * |
10.1
x | P/E ratio 2025 * |
7.5
x | Employees | - |
| Yield 2024 * |
1.78% | Yield 2025 * |
2.08% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on ONCS BRAS
| 1 day | -2.15% | ||
| 1 week | -6.69% | ||
| Current month | -7.20% | ||
| 1 month | -10.95% | ||
| 3 months | -36.93% | ||
| 6 months | -33.62% | ||
| Current year | -47.46% |
1 week
5.38
7.57
1 month
5.387.93
Current year
5.3812.95
1 year
5.3813.00
3 years
4.0319.62
5 years
4.0319.62
10 years
4.0319.62
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/24/14 | 6.83 | -2.15% | 3 080 600 |
| 10/24/10 | 6.98 | +15.37% | 6,100,600 |
| 09/24/09 | 6.05 | -3.66% | 17,750,100 |
| 08/24/08 | 6.28 | -15.93% | 15,302,800 |
| 07/24/07 | 7.47 | +2.05% | 3,088,500 |
Delayed Quote Sao Paulo, May 14, 2024 at 12:58 am IST
More quotes
Oncoclinicas do Brasil Servicos Medicos SA is a Brazil-based company engaged in the outpatient medical services sector. The company provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The company holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Sector
-
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.98
BRL
Average target price
14.83
BRL
Spread / Average Target
+112.51%
EPS Revisions
- Stock Market
- Equities
- ONCO3 Stock